Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.'s Transaction with Neurocrine is Fair to Public Shareholders
Ademi LLP is investigating Soleno Therapeutics Inc. (NASDAQ: SLNO) regarding its transaction with Neurocrine, which offers Soleno shareholders $53.00 per share, totaling $2.9 billion. The investigation will determine if Soleno's board of directors fulfilled their fiduciary duties, especially considering potential restrictions on competing bids. The firm specializes in shareholder litigation concerning buyouts, mergers, and individual shareholder rights.
Neurocrine nears $2.5B-plus deal to buy Soleno Therapeutics - FT (NBIX:NASDAQ)
Neurocrine Biosciences is reportedly in advanced talks to acquire Soleno Therapeutics for over $2.5 billion. The deal would value Soleno, known for its drug treating extreme hunger in Prader-Willi syndrome, in the low-to-mid $50s per share. This potential acquisition highlights Neurocrine's expansion strategy in the biotech sector.
Neurocrine nears $2.5 billion deal for Soleno Therapeutics, FT reports
Neurocrine Biosciences is reportedly close to acquiring Soleno Therapeutics in a deal valued at approximately $2.5 billion, according to an FT report. This brief news item suggests a significant merger and acquisition activity in the pharmaceutical sector. The report from Reuters was published by TradingView.
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025, and November 4, 2025, about the May 5, 2026 lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Soleno Therapeutics made false and misleading statements regarding the safety and commercial viability of its drug, diazoxide choline extended-release tablets (DCCR), for Prader-Willi syndrome, specifically related to undisclosed safety concerns like excess fluid retention. Investors who suffered damages are encouraged to join the class action to seek compensation.
Do Ongoing DCCR Lawsuits Reframe Soleno Therapeutics’ (SLNO) Risk Profile More Than Its Drug Potential?
Soleno Therapeutics is facing multiple securities class action lawsuits alleging undisclosed material safety concerns and data integrity issues related to its Prader-Willi syndrome drug, DCCR (VYKAT XR). These lawsuits, focusing on claims like fluid retention and high discontinuation rates, could significantly impact investor perception, regulatory assessment, and the company's financial forecasts. The legal challenges add to existing scrutiny and may influence prescribers and payers, potentially limiting the drug's long-term treatability despite its early market traction.
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO
ClaimsFiler is alerting investors of Soleno Therapeutics, Inc. (NasdaqCM: SLNO) who incurred losses exceeding $100,000 to file lead plaintiff applications by May 5, 2026. The class action lawsuit, pending in California, alleges that Soleno failed to disclose material information regarding potential safety concerns and commercial viability risks of its drug DCCR for Prader-Willi syndrome. Soleno and its executives are accused of minimizing evidence of excessive fluid retention in clinical trials, leading to undisclosed safety risks and lower commercial prospects for the drug.
Soleno Therapeutics Faces Lawsuit After DCCR Launch Setback and Share Drop
A class action lawsuit has been filed against Soleno Therapeutics (NASDAQ: SLNO) on behalf of investors who bought stock between March 26, 2025, and November 4, 2025. The lawsuit alleges that Soleno misrepresented the commercial prospects and downplayed safety concerns of its drug DCCR (VYKAT™ XR), which led to a 26% share price drop after a disappointing launch report. Hagens Berman is investigating these claims, following a short seller's report that highlighted safety issues and a subsequent "disruption in launch trajectory" acknowledged by Soleno.
Soleno Therapeutics Investors Eligible to Lead Securities Fraud Lawsuit
The Schall Law Firm has announced an opportunity for investors in Soleno Therapeutics, Inc. to lead a securities fraud class action lawsuit against the biotech company. The lawsuit alleges that Soleno Therapeutics made false and misleading statements about the development and regulatory status of its lead drug candidate, DCCR, for Prader-Willi syndrome, which failed to receive FDA approval. This case highlights the importance of transparency in publicly traded biotech companies.
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities between March 26, 2025, and November 4, 2025, to join a class action lawsuit. The lawsuit alleges that Soleno made false and misleading statements about the safety and commercial viability of its DCCR treatment during its Phase 3 clinical trial. Investors who suffered losses are advised to contact the firm before May 5, 2026, to participate.
Banque Pictet & Cie SA Takes $2.03 Million Position in Soleno Therapeutics, Inc. $SLNO
Banque Pictet & Cie SA has acquired a new stake of 43,796 shares, valued at approximately $2.03 million, in Soleno Therapeutics, Inc. (NASDAQ:SLNO) during the fourth quarter. Institutional investors now collectively own about 97.42% of the company. However, Soleno Therapeutics is facing legal challenges, including a securities class action lawsuit, and analyst sentiment is mixed, with some downgrades and reduced price targets despite a "Moderate Buy" consensus rating.
H.C. Wainwright cuts Soleno Therapeutics stock price target to $100
H.C. Wainwright has lowered its price target for Soleno Therapeutics (NASDAQ:SLNO) from $120 to $100, while maintaining a Buy rating. This adjustment follows news of Soleno reporting $190.4 million in 2025 VYKAT XR net sales and having a strong financial position with more cash than debt and a high current ratio. The firm also cited a less competitive landscape for VYKAT XR and the stock being undervalued according to InvestingPro analysis as factors.
Soleno Therapeutics Faces Class Action Lawsuit Over Drug Trial Concerns
Soleno Therapeutics is facing a class action lawsuit alleging securities fraud. The lawsuit claims the company concealed significant safety concerns during its Phase 3 clinical trial for DCCR, a treatment for Prader-Willi syndrome. Investors who purchased Soleno stock between March 26, 2025, and November 4, 2025, have until May 5, 2026, to file for lead plaintiff status.
Soleno Therapeutics, Inc. Class Action Lawsuit: Investors Face May 5, 2026, Deadline
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) on behalf of investors who purchased common stock between March 26, 2025, and November 4, 2025. The lawsuit alleges that Soleno made materially false and misleading statements and/or omissions regarding the safety concerns related to its Phase 3 clinical trial program for DCCR. Investors impacted by the alleged misstatements and subsequent stock drop, which occurred after a report by Scorpion Capital, LLC, have until May 5, 2026, to seek lead plaintiff status.
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT
Bernstein Liebhard LLP has issued a shareholder alert for Soleno Therapeutics, Inc. (SLNO) reminding investors of an upcoming deadline, May 5, 2026, to file as a lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that Soleno and its senior officers made misrepresentations regarding the company's Phase 3 clinical trial program for DCCR. Investors who purchased Soleno common stock between March 26, 2025, and August 4, 2025, and incurred losses may be eligible to join.
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds
ClaimsFiler is reminding investors who suffered losses exceeding $100,000 in Soleno Therapeutics, Inc. (NasdaqCM: SLNO) to file lead plaintiff applications by May 5, 2026, in a securities class action lawsuit. The lawsuit alleges that Soleno and its executives failed to disclose material information regarding potential safety concerns and risks associated with their DCCR product's Phase 3 clinical trial for Prader-Willi syndrome. These alleged omissions relate to evidence of excessive fluid retention and the resulting impact on DCCR's commercial viability and safety profile.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SLNO
Pomerantz LLP has filed a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO), advising investors who suffered losses to contact them. The lawsuit alleges securities fraud, referencing a Scorpion Capital report questioning the safety and pricing of Soleno's drug DCCR, followed by disclosures of a patient death and high discontinuation rates due to adverse effects, which led to significant drops in Soleno's stock price. Investors have until May 5, 2026, to seek appointment as Lead Plaintiff.
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT
Bernstein Liebhard LLP reminds investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) about an upcoming deadline for a securities fraud class action lawsuit. The lawsuit alleges misrepresentations regarding the company's Phase 3 clinical trial program for DCCR for investors who purchased shares between March 26, 2025, and August 4, 2025. Shareholders who lost money are encouraged to contact the law firm to discuss their legal options or consider serving as lead plaintiff by May 5, 2026.
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has issued a notice regarding a class action securities lawsuit against Soleno Therapeutics, Inc. (NasdaqCM:SLNO). The lawsuit seeks to recover losses for investors affected by alleged securities fraud between March 26, 2025, and November 4, 2025, concerning undisclosed safety risks of the company's DCCR product. Investors who suffered losses have until May 5, 2026, to apply to be appointed as lead plaintiff.
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky
Levi & Korsinsky, LLP has issued an investor alert regarding a securities class action against Soleno Therapeutics, Inc. (NASDAQ: SLNO). The lawsuit alleges that Soleno made misrepresentations about the integrity and safety of its clinical trials for DCCR (VYKAT XR), a drug for Prader-Willi syndrome, after the sole pivotal Phase 3 study was called into question. Investors who purchased Soleno securities between March 26, 2025, and November 4, 2025, have until May 5, 2026, to seek lead plaintiff status.
REMINDER: Soleno Therapeutics, Inc. Investors With Significant Losses Must Act By May 5, 2026 – Contact Kirby McInerney
Kirby McInerney LLP reminds Soleno Therapeutics, Inc. (NASDAQ:SLNO) investors that they have until May 5, 2026, to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Soleno downplayed safety concerns related to its DCCR clinical trial program, leading to significant stock price declines following reports of safety issues, patient death, and high discontinuation rates. Investors who suffered losses are encouraged to contact the law firm to discuss their rights.
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced that Soleno Therapeutics, Inc. (SLNO) investors who experienced losses have an opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that Soleno misrepresented safety concerns related to its DCCR clinical trial program, specifically concerning excess fluid retention and higher safety risks than disclosed, which negatively impacted commercial viability. Investors who suffered losses between March 26, 2025, and November 4, 2026, are encouraged to contact the firm before the May 5, 2026, lead plaintiff deadline.
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky
Levi & Korsinsky, LLP reminds investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) about a pending securities class action lawsuit. The lawsuit alleges that the company made misrepresentations regarding the integrity of its clinical trials for DCCR (VYKAT XR), its sole commercial product for Prader-Willi syndrome. Investors who purchased Soleno securities between March 26, 2025, and November 4, 2025, may be entitled to compensation and have until May 5, 2026, to seek lead plaintiff status.
Soleno Therapeutics Investors Seek Compensation After Losses
A class action lawsuit has been filed against Soleno Therapeutics, Inc. (SLNO) by Robbins LLP on behalf of investors who experienced losses due to a decline in the company's stock price. The lawsuit alleges that Soleno Therapeutics made misleading statements regarding its business and financial performance, particularly about its lead drug candidate, causing artificial inflation of its stock. When setbacks in the drug's development were disclosed, the stock price plummeted, resulting in significant investor losses.
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Soleno Therapeutics, Inc. (NasdaqCM: SLNO) on behalf of investors who suffered losses between March 26, 2025, and November 4, 2025. The lawsuit alleges Soleno and its executives failed to disclose material information regarding potential safety concerns and lower commercial viability of its Prader-Willi syndrome drug, DCCR. Investors have until May 5, 2026, to request to be appointed as lead plaintiff.
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application
Kahn Swick & Foti, LLC (KSF) has notified investors in Soleno Therapeutics, Inc. (NasdaqCM: SLNO) of a class action securities lawsuit. The lawsuit alleges that Soleno and its executives failed to disclose material information regarding the safety risks and commercial viability of its product, DCCR, for Prader-Willi syndrome. Investors who suffered losses between March 26, 2025, and November 4, 2025, have until May 5, 2026, to request to be appointed as lead plaintiff.
Soleno (NASDAQ: SLNO) SVP sells 6,582 shares to cover RSU tax obligations
Michael F. Huang, Senior Vice President of Clinical Development at Soleno Therapeutics (NASDAQ: SLNO), sold 6,582 shares of company common stock on March 27, 2026. These sales, conducted in multiple trades at weighted average prices between $30 and $32 per share, were primarily to cover tax obligations arising from the vesting of restricted stock units (RSUs). After these transactions, Huang retains direct ownership of 39,823 shares of Soleno common stock.
Soleno Therapeutics: Huang sells $200k in shares
Michael F. Huang, Sr. VP of Clinical Development at Soleno Therapeutics Inc, sold 6,582 shares for over $200,000 to cover tax withholding obligations. This insider sale comes as SLNO stock is trading near its 52-week low, despite the company reporting strong Q4 2025 financial results and making a new CFO appointment. Analyst price targets have been lowered, but ratings remain positive.
Soleno (SLNO) CCO sells 7,522 shares to cover RSU tax obligations
Soleno Therapeutics' Chief Commercial Officer, Meredith Manning, sold 7,522 shares of common stock on March 27, 2026, to cover tax withholding obligations associated with vesting restricted stock units (RSUs). Following these transactions, Manning directly holds 64,507 shares. The sales were executed in multiple trades at weighted average prices ranging from $30.0370 to $31.7187 per share.
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application
Kahn Swick & Foti, LLC (KSF) has notified investors in Soleno Therapeutics, Inc. (NasdaqCM: SLNO) of a class action securities lawsuit. The lawsuit alleges that Soleno and its executives failed to disclose material information regarding potential safety concerns and lower commercial viability of their drug DCCR, affecting investors who purchased shares between March 26, 2025, and November 4, 2025. Investors have until May 5, 2026, to request to be appointed as lead plaintiff.
SLNO Stockholders Have Rights – If You Lost Money Investing
Robbins LLP reminds stockholders that a class action has been filed against Soleno Therapeutics (NASDAQ: SLNO) on behalf of investors who purchased shares between March 26, 2025, and November 4, 2025. The lawsuit alleges that Soleno misled investors regarding safety concerns and commercial viability of its DCCR drug for Prader-Willi syndrome. Shareholders who wish to act as lead plaintiff must submit their papers to the court by May 5, 2026.
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ:SLNO) on behalf of investors who purchased securities between March 26, 2025, and November 4, 2025. The lawsuit alleges that Soleno failed to disclose significant safety concerns related to its DCCR clinical trial program, including issues of excess fluid retention and higher safety risks than disclosed, which negatively impacted DCCR's commercial viability. Investors who suffered losses have until May 5, 2026, to request to be appointed as lead plaintiff.
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is encouraging investors who purchased Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities between March 26, 2025, and November 4, 2025, to join a class action lawsuit. The lawsuit alleges securities fraud, claiming Soleno made false and misleading statements by downplaying safety concerns and commercial viability issues related to its DCCR treatment's Phase 3 clinical trial. Investors are urged to contact the firm before May 5, 2026, to participate and potentially recover losses.
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO), encouraging those who purchased shares between March 26, 2025, and November 4, 2025, to join a securities class action lawsuit. The complaint alleges that Soleno Therapeutics made misleading statements and failed to disclose safety concerns related to its DCCR clinical trial, including issues with excess fluid retention, which negatively impacted the drug's commercial viability. Shareholders have until May 5, 2026, to register as a lead plaintiff.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)
Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (SLNO) on behalf of investors who purchased shares between March 26, 2025, and August 4, 2025. The lawsuit alleges misrepresentations regarding the company's Phase 3 clinical trial for DCCR. Investors are encouraged to contact the firm to discuss their legal rights, with a lead plaintiff deadline of May 5, 2026.
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities
Levi & Korsinsky, LLP has issued an investor alert regarding a securities fraud lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO). The lawsuit alleges that Soleno's management concealed material safety risks related to its drug VYKAT XR, approved for Prader-Willi syndrome. Institutional investors who held SLNO shares between March 26, 2025, and November 4, 2025, are encouraged to evaluate lead plaintiff opportunities, with a deadline of May 5, 2026, to apply.
Deadline Alert: Soleno Therapeutics, Inc. (SLNO)
Glancy Prongay Wolke & Rotter LLP is urging investors of Soleno Therapeutics, Inc. (SLNO) who suffered losses to contact them regarding a securities fraud lawsuit. The lawsuit alleges that Soleno made misleading statements and failed to disclose material adverse facts concerning its DCCR drug for Prader-Willi syndrome, specifically regarding safety concerns, clinical trial conduct, and commercial viability, after reports by activist investor Scorpion Capital and subsequent patient death and financial results showed negative impacts. Investors have until May 5, 2026, to file a lead plaintiff motion in the class action.
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) who purchased securities between March 6, 2025, and November 4, 2025. The lawsuit alleges that Soleno concealed significant safety evidence within its Phase 3 clinical trial program, particularly regarding "excess fluid retention" related to its lead drug DCCR, which impacted its commercial launch and stock price. Investors are encouraged to contact the law firm by May 5, 2026, to discuss their legal rights.
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ:SLNO) and its officers. The lawsuit alleges that Soleno Therapeutics failed to disclose significant safety concerns related to its Phase 3 clinical trial for DCCR, specifically regarding fluid retention and the drug's commercial viability. Shareholders who suffered losses between March 26, 2025, and November 4, 2025, are encouraged to join the lawsuit and have until May 5, 2026, to request to be appointed lead plaintiff.
ROSEN, A TOP-RANKED LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
The Rosen Law Firm is reminding investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) who purchased common stock between March 26, 2025, and November 4, 2025, about the May 5, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that Soleno made false and misleading statements regarding the safety and commercial viability of its DCCR drug for Prader-Willi syndrome, specifically related to undisclosed safety concerns and fluid retention issues in clinical trials. Investors are encouraged to seek counsel to potentially recover losses through a contingency fee arrangement.
SLNO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Faruqi & Faruqi, LLP is investigating potential securities class action claims against Soleno Therapeutics (SLNO) and reminds investors of the May 5, 2026, lead plaintiff deadline. The investigation follows allegations that Soleno made false and/or misleading statements regarding the safety risks and commercial viability of its drug DCCR for Prader-Willi syndrome. Soleno's stock declined significantly after reports from Scorpion Capital regarding safety concerns, a patient death, and disrupted drug launch.
Vanguard disaggregates holdings; reports 0 shares of Soleno Therapeutics (SLNO)
Vanguard has filed a Schedule 13G/A amendment reporting zero beneficial ownership of Soleno Therapeutics (SLNO) common stock, representing 0% of its class. This change is a result of an internal realignment effective January 12, 2026, which disaggregates reporting; Vanguard's subsidiaries will now report their beneficial ownership separately. The filing does not indicate any market transactions but clarifies reporting structure.
Kaplan Fox Reminds Investors of Soleno Therapeutics, Inc. (SLNO) to a Class Action Deadline on May 5, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Soleno Therapeutics, Inc. (SLNO) on behalf of investors who bought securities between March 26, 2025, and November 4, 2025. The lawsuit alleges that Soleno systematically downplayed safety concerns related to its drug DCCR and that critical reports from Scorpion Capital led to significant stock price declines. Investors have until May 5, 2026, to move the court to serve as a lead plaintiff.
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has issued a notice to investors of Soleno Therapeutics, Inc. (NasdaqCM: SLNO) regarding a class action securities lawsuit. The lawsuit alleges that Soleno and its executives failed to disclose material information regarding potential safety concerns with its drug DCCR during its Phase 3 clinical trial program, affecting investors who suffered losses between March 26, 2025, and November 4, 2025. Investors have until May 5, 2026, to request to be appointed as lead plaintiff.
SLNO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and some of its officers. The lawsuit alleges that Soleno failed to disclose significant safety concerns associated with its DCCR Phase 3 clinical trial drug, particularly regarding fluid retention issues and its potential impact on commercial viability. Investors who purchased Soleno securities between March 26, 2025, and November 4, 2025, are encouraged to join the lawsuit, with a deadline of May 5, 2026, to request to be appointed as lead plaintiff.
Assenagon Asset Management S.A. Purchases New Position in Soleno Therapeutics, Inc. $SLNO
Assenagon Asset Management S.A. has acquired a new position of 384,166 shares, valued at approximately $17.8 million, in Soleno Therapeutics, Inc. (NASDAQ:SLNO), bringing institutional ownership to about 97.4%. This comes amid several securities class action lawsuits against Soleno Therapeutics regarding DCCR disclosures, with a lead-plaintiff deadline of May 5, 2026. Analyst ratings are generally cautious with a "Moderate Buy" consensus and an average target price of $102.60, though some have recently lowered ratings and price objectives.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)
Bernstein Liebhard LLP has announced a securities class action lawsuit against Soleno Therapeutics, Inc. (SLNO) on behalf of investors who purchased or acquired common stock between March 26, 2025, and August 4, 2025. The lawsuit alleges that Soleno Therapeutics made misrepresentations concerning its Phase 3 clinical trial program for DCCR. Shareholders who wish to serve as lead plaintiff must file papers by May 5, 2026.
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting DCCR Safety Timeline: SueWallSt
A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO), alleging that the company and its executives misrepresented the safety profile of VYKAT XR (diazoxide choline extended-release tablets) between March 26, 2025, and November 4, 2025. Investors who purchased SLNO securities during this period and suffered losses are encouraged to contact SueWallSt to potentially lead the class action. The lawsuit claims Soleno concealed serious adverse event risks tied to the drug, including fluid retention, pre-diabetes, and potential heart failure, despite numerous public assurances about its safety.
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Soleno Therapeutics, Inc. common stock between March 26, 2025, and November 4, 2025, of the upcoming May 5, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Soleno made false and misleading statements regarding the safety and commercial viability of its DCCR drug for Prader-Willi syndrome, specifically concerning unaddressed safety risks like excess fluid retention. Investors are encouraged to join the class action to seek compensation.
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Drug Safety Risks: Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) on behalf of investors who purchased securities between March 26, 2025, and November 4, 2025. The lawsuit alleges that Soleno systematically downplayed significant safety concerns related to its drug DCCR (VYKAT XR), including fluid retention, elevated diabetes risk, and potential pulmonary edema. Investors with losses related to these alleged misrepresentations are encouraged to seek to lead the class action by May 5, 2026.
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline For Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Soleno Therapeutics, Inc. (NasdaqCM:SLNO) for alleged securities fraud between March 26, 2025, and November 4, 2025. The lawsuit claims Soleno failed to disclose material information regarding potential safety concerns of its product DCCR during its Phase 3 clinical trials, implying greater risks than disclosed and lower commercial viability. Investors affected by losses during this period have until May 5, 2026, to apply to be a lead plaintiff.
